BioMarin ‘turning the corner’ on profits with optimism on Voxzogo, Roctavian — but questions remain
BioMarin finally is ‘turning the corner’ on profitability in 2022, CEO Jean-Jacques Bienaimé said in its earnings call yesterday. And while investors generally agreed with that, they also have a lot of specific product questions that BioMarin isn’t able to fully answer just yet.
For instance, on its achondroplasia drug Voxzogo specific to children in its youngest age cohort ages 0-5, BioMarin detailed new top-line Phase II data and a miss, with no statistical significance found among the young patients. However executives cautioned the data is new, received “only 24 hours ago,” and “a little complicated in signal and noise” during its earnings call Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.